

Don't Jump to Albumin for Decompensated Liver Disease

You'll be asked about **the role of IV albumin in patients hospitalized with acute decompensated liver disease**.

New evidence shows that giving these patients DAILY albumin to raise and maintain levels above 3 g/dL does NOT reduce infection, kidney dysfunction, or death.

Plus albumin may increase pulmonary edema risk...and costs about \$120 per 25 g dose.

Continue to avoid routine use of albumin in stable floor patients admitted with new or worsening ascites...hepatic encephalopathy...or a suspected variceal bleed.

But some patients with acute decompensated liver disease may still need albumin.

For example, use albumin to prevent central volume depletion in those undergoing large-volume paracentesis...removing over 5 L.

And give albumin for spontaneous bacterial peritonitis IF there's a risk of renal dysfunction...BUN over 30 mg/dL, serum creatinine above 1 mg/dL, or total bilirubin over 4 mg/dL.

Also continue to think of albumin to resuscitate a septic shock patient who isn't responding to adequate crystalloids.

Create an order set with indications to help with albumin dosing.

For example, give 1.5 g/kg, then 1 g/kg two days later for spontaneous bacterial peritonitis. But for shock, use 12.5 g to 25 g boluses until mean arterial pressure and other markers improve.

When giving albumin in liver disease, generally use the 25% product. Its oncotic pressure draws fluid into the intravascular space.

Typically max the 25% albumin rate at 2 mL/min for nonemergent use...to limit fluid overload. Monitor for respiratory distress, hypertension, etc...especially with heart failure or other risks.

See our FAQ, *Decompensated Chronic Liver Failure*, for more on treating ascites, encephalopathy, acute bleeding, etc.

Key References:

-N Engl J Med 2021;384(9):808-17

-Hepatology 2013;57(4):1651-3

-Medication pricing by Elsevier, accessed May 2021

Hospital Pharmacist's Letter. June 2021, No. 370616

Cite this document as follows: Article, Don't Jump to Albumin for Decompensated Liver Disease, Hospital Pharmacist's Letter, June 2021

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email sales@trchealthcare.com.

© 2021 Therapeutic Research Center (TRC). TRC and Hospital Pharmacist's Letter and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved. | 3120 W. March Lane, Stockton, CA, 95219 | (209) 472-2240